Blommaert AG - Search Results

1

Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties.

Blommaert AG, Weng JH, Dorville A, McCort I, Ducos B, Durieux C, Roques BP. Blommaert AG, et al. J Med Chem. 1993 Oct 1;36(20):2868-77. doi: 10.1021/jm00072a005. J Med Chem. 1993. PMID: 8411002

2

Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.

Weng JH, Blommaert AG, Moizo L, Bado A, Ducos B, Böhme A, Garbay C, Roques BP. Weng JH, et al. Among authors: blommaert ag. Bioorg Med Chem. 1996 Apr;4(4):563-73. doi: 10.1016/0968-0896(96)00050-8. Bioorg Med Chem. 1996. PMID: 8735845

3

Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.

Blommaert AG, Dhôtel H, Ducos B, Durieux C, Goudreau N, Bado A, Garbay C, Roques BP. Blommaert AG, et al. J Med Chem. 1997 Feb 28;40(5):647-58. doi: 10.1021/jm9603072. J Med Chem. 1997. PMID: 9057851

4

Thio-derived disulfides as potent inhibitors of botulinum neurotoxin type B: implications for zinc interaction.

Anne C, Blommaert A, Turcaud S, Martin AS, Meudal H, Roques BP. Anne C, et al. Bioorg Med Chem. 2003 Oct 15;11(21):4655-60. doi: 10.1016/s0968-0896(03)00450-4. Bioorg Med Chem. 2003. PMID: 14527562

5

Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metallo-proteolytic activity.

Blommaert A, Turcaud S, Anne C, Roques BP. Blommaert A, et al. Bioorg Med Chem. 2004 Jun 1;12(11):3055-62. doi: 10.1016/j.bmc.2004.03.006. Bioorg Med Chem. 2004. PMID: 15142564

6

The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats.

Derrien M, Daugé V, Blommaert A, Roques BP. Derrien M, et al. Behav Brain Res. 1994 Dec 15;65(2):139-46. doi: 10.1016/0166-4328(94)90098-1. Behav Brain Res. 1994. PMID: 7718145

7

A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.

Noble F, Blommaert A, Fournié-Zaluski MC, Roques BP. Noble F, et al. Eur J Pharmacol. 1995 Jan 24;273(1-2):145-51. doi: 10.1016/0014-2999(94)00688-4. Eur J Pharmacol. 1995. PMID: 7737308

8

CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration.

Durieux C, Derrien M, Maldonado R, Valverde O, Blommaert A, Fournié-Zaluski MC, Roques BP. Durieux C, et al. Ann N Y Acad Sci. 1994 Mar 23;713:355-7. doi: 10.1111/j.1749-6632.1994.tb44091.x. Ann N Y Acad Sci. 1994. PMID: 8185186 No abstract available.

9

The CCK-B agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats.

Ladurelle N, Keller G, Blommaert A, Roques BP, Daugé V. Ladurelle N, et al. Eur J Neurosci. 1997 Sep;9(9):1804-14. doi: 10.1111/j.1460-9568.1997.tb00747.x. Eur J Neurosci. 1997. PMID: 9383203

10

Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.

Valverde O, Blommaert AG, Fournié-Zaluski MC, Roques BP, Maldonado R. Valverde O, et al. Among authors: blommaert ag. Eur J Pharmacol. 1995 Nov 3;286(1):79-93. doi: 10.1016/0014-2999(95)00435-n. Eur J Pharmacol. 1995. PMID: 8566154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters